OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+3.09%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$406M
AUM Growth
+$406M
(-16%)
Cap. Flow
-$48M
Cap. Flow
% of AUM
-11.81%
Top 10 Holdings %
Top 10 Hldgs %
73.39%
Holding
37
New
3
Increased
6
Reduced
12
Closed
7
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$11.2M |
| 2 |
Celldex Therapeutics
CLDX
|
$10.8M |
| 3 |
Cytek Biosciences
CTKB
|
$10.7M |
| 4 |
BridgeBio Pharma
BBIO
|
$8.83M |
| 5 |
Arcus Biosciences
RCUS
|
$7.32M |
Top Sells
| 1 |
Zai Lab
ZLAB
|
$19.4M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$14.1M |
| 3 |
IMAB
I-MAB
IMAB
|
$13M |
| 4 |
Curis
CRIS
|
$10.1M |
| 5 |
Vera Therapeutics
VERA
|
$7.57M |
Sector Composition
| 1 | Healthcare | 99.28% |
| 2 | Financials | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMAB
1
I-MAB
IMAB
$340M
| $55.4M | 13.64% | 764,461 -178,695 | -19% | -$13M |
|
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $52.6M | 12.95% | 1,595,911 +339,646 | +27% | +$11.2M |
|
|
3
Celldex Therapeutics
CLDX
$1.47B
| $41.1M | 10.12% | 761,398 +200,000 | +36% | +$10.8M |
|
|
4
Arcus Biosciences
RCUS
$1.13B
| $33.8M | 8.33% | 970,164 +210,000 | +28% | +$7.32M |
|
|
5
BridgeBio Pharma
BBIO
$9.89B
| $26.7M | 6.57% | 569,414 +188,486 | +49% | +$8.83M |
|
6
4D Molecular Therapeutics
FDMT
$288M
| $22.4M | 5.52% | 831,267 | – | – |
|
7
Gossamer Bio
GOSS
$562M
| $19M | 4.68% | 1,513,138 +100,000 | +7% | +$1.26M |
|
|
8
Curis
CRIS
$20.9M
| $18M | 4.42% | 2,294,721 -1,287,908 | -36% | -$10.1M |
|
9
Century Therapeutics
IPSC
$42.5M
| $15.2M | 3.73% | 602,623 +199,100 | +49% | +$5.01M |
|
10
Arvinas
ARVN
$568M
| $13.8M | 3.41% | 168,500 -10,000 | -6% | -$822K |
|
|
11
Vera Therapeutics
VERA
$1.38B
| $12.1M | 2.97% | 696,126 -436,545 | -39% | -$7.57M |
|
12
Avidity Biosciences
RNA
$5.99B
| $11M | 2.71% | 446,641 | – | – |
|
|
13
Cytek Biosciences
CTKB
$527M
| $10.7M | 2.64% | +500,000 | New | +$10.7M |
|
14
Dyne Therapeutics
DYN
$1.92B
| $9.48M | 2.33% | 583,649 | – | – |
|
|
CNTB
15
Connect Biopharma
CNTB
$115M
| $7.8M | 1.92% | 326,143 -47,349 | -13% | -$1.13M |
|
16
Stoke Therapeutics
STOK
$1.08B
| $7.55M | 1.86% | 296,822 | – | – |
|
|
OMGA
17
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $6.98M | 1.72% | +370,279 | New | +$6.98M |
|
18
Cardiff Oncology
CRDF
$140M
| $6.55M | 1.61% | 982,753 | – | – |
|
|
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $4.74M | 1.17% | 200,000 | – | – |
|
|
AMAM
20
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $4.73M | 1.16% | 350,000 -100,000 | -22% | -$1.35M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.5M | 1.11% | 277,057 -402,979 | -59% | -$6.54M |
|
|
NGM
22
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $4.2M | 1.04% | 200,000 | – | – |
|
23
MoonLake Immunotherapeutics
MLTX
$3.54B
| $3.95M | 0.97% | 400,000 | – | – |
|
|
IMA
24
ImageneBio, Inc. Common Stock
IMA
$150M
| $3.47M | 0.85% | 275,000 -125,000 | -31% | -$1.58M |
|
25
Monte Rosa Therapeutics
GLUE
$296M
| $3.34M | 0.82% | 150,000 -88,045 | -37% | -$1.96M |
|